CN102813916B - 一种快速获取树突状细胞疫苗的制备方法及其应用 - Google Patents
一种快速获取树突状细胞疫苗的制备方法及其应用 Download PDFInfo
- Publication number
- CN102813916B CN102813916B CN201210324704.5A CN201210324704A CN102813916B CN 102813916 B CN102813916 B CN 102813916B CN 201210324704 A CN201210324704 A CN 201210324704A CN 102813916 B CN102813916 B CN 102813916B
- Authority
- CN
- China
- Prior art keywords
- cell
- culture
- cd11c
- dendritic cell
- labelling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 229940030156 cell vaccine Drugs 0.000 title abstract 6
- 102100022297 Integrin alpha-X Human genes 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract description 15
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract description 15
- 102100035793 CD83 antigen Human genes 0.000 claims abstract description 13
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims abstract description 13
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims abstract description 13
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims abstract description 13
- 230000000139 costimulatory effect Effects 0.000 claims abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 7
- 238000011160 research Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 71
- 210000004443 dendritic cell Anatomy 0.000 claims description 31
- 238000002372 labelling Methods 0.000 claims description 30
- 229940029030 dendritic cell vaccine Drugs 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 27
- 108091007433 antigens Proteins 0.000 claims description 27
- 239000001963 growth medium Substances 0.000 claims description 21
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 18
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 18
- 150000001720 carbohydrates Chemical class 0.000 claims description 18
- 210000005087 mononuclear cell Anatomy 0.000 claims description 14
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 14
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 12
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 8
- 230000003833 cell viability Effects 0.000 claims description 7
- 238000004043 dyeing Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 235000020776 essential amino acid Nutrition 0.000 claims description 6
- 239000003797 essential amino acid Substances 0.000 claims description 6
- 230000012447 hatching Effects 0.000 claims description 6
- 229940054269 sodium pyruvate Drugs 0.000 claims description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000012531 culture fluid Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 abstract description 4
- 108090000288 Glycoproteins Proteins 0.000 abstract description 4
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 235000014633 carbohydrates Nutrition 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 101150047061 tag-72 gene Proteins 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 230000005975 antitumor immune response Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102000051366 Glycosyltransferases Human genes 0.000 description 4
- 108700023372 Glycosyltransferases Proteins 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 101100382123 Mus musculus Ciita gene Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101100476202 Caenorhabditis elegans mog-2 gene Proteins 0.000 description 1
- 101100244735 Caenorhabditis elegans saps-1 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- -1 glycosyl sphingolipid Chemical class 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210324704.5A CN102813916B (zh) | 2012-09-05 | 2012-09-05 | 一种快速获取树突状细胞疫苗的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210324704.5A CN102813916B (zh) | 2012-09-05 | 2012-09-05 | 一种快速获取树突状细胞疫苗的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102813916A CN102813916A (zh) | 2012-12-12 |
CN102813916B true CN102813916B (zh) | 2015-03-11 |
Family
ID=47298598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210324704.5A Expired - Fee Related CN102813916B (zh) | 2012-09-05 | 2012-09-05 | 一种快速获取树突状细胞疫苗的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102813916B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784950A (zh) * | 2014-01-22 | 2014-05-14 | 北京弘润源生物技术有限公司 | 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒 |
CN105154403A (zh) * | 2015-07-09 | 2015-12-16 | 深圳爱生再生医学科技有限公司 | 树突状细胞抗原负载方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1569235A (zh) * | 2004-04-28 | 2005-01-26 | 郭军 | 热疗促进树突状细胞疫苗功能临床治疗恶性实体瘤 |
CN1744822A (zh) * | 2002-12-04 | 2006-03-08 | 贝勒研究院 | 从前体产生加载有抗原的树突细胞疫苗的快速一步法 |
CN102154208A (zh) * | 2010-12-28 | 2011-08-17 | 沈达青 | Cd133+脑胶质瘤干细胞抗原负载树突状细胞的制法及其应用 |
CN102337244A (zh) * | 2010-07-21 | 2012-02-01 | 叶渭龙 | 经化疗药物耐受性筛选的肿瘤细胞抗原负载树突状细胞及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050118185A1 (en) * | 2003-06-18 | 2005-06-02 | Cell Center Cologne Gmbh | Recombinant immunoreceptors |
CN1282485C (zh) * | 2005-04-04 | 2006-11-01 | 南京大陆产业投资集团有限公司 | 负载凋亡的热休克肿瘤细胞的树突状细胞肿瘤疫苗及其制备方法与应用 |
EP1920782A1 (en) * | 2006-11-10 | 2008-05-14 | Glycotope Gmbh | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
CN101461942B (zh) * | 2008-08-27 | 2010-07-21 | 时宏珍 | 负载重组人hsp70多肽复合物的树突状细胞疫苗、制备方法与应用 |
-
2012
- 2012-09-05 CN CN201210324704.5A patent/CN102813916B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1744822A (zh) * | 2002-12-04 | 2006-03-08 | 贝勒研究院 | 从前体产生加载有抗原的树突细胞疫苗的快速一步法 |
CN1569235A (zh) * | 2004-04-28 | 2005-01-26 | 郭军 | 热疗促进树突状细胞疫苗功能临床治疗恶性实体瘤 |
CN102337244A (zh) * | 2010-07-21 | 2012-02-01 | 叶渭龙 | 经化疗药物耐受性筛选的肿瘤细胞抗原负载树突状细胞及其制备方法和应用 |
CN102154208A (zh) * | 2010-12-28 | 2011-08-17 | 沈达青 | Cd133+脑胶质瘤干细胞抗原负载树突状细胞的制法及其应用 |
Non-Patent Citations (4)
Title |
---|
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors;Andrew J. Lepisto et al.;《Cancer Ther》;20081231;第6卷(第B期);第955-964页 * |
Clinical and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma;Yukino Kimura et al.;《Pancreas》;20120331;第41卷(第2期);第198页左栏最后1段-右栏第2段,摘要"Conclusions","Patients, Treatment, and Sampling"部分 * |
干扰素-α联合GM_CSF诱导慢性髓性白血病细胞向树突状细胞分化;金洁等;《中国病理生理杂志》;20061231;第22卷(第3期);摘要、第"2.1"节、第"2.3节" * |
朱正美等.树突状细胞的体外制备.《简明免疫学技术》.科学技术出版社,2002,第20-21页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102813916A (zh) | 2012-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105087487B (zh) | 一种高效扩增cik的方法 | |
CN102600462B (zh) | 人树突状细胞肿瘤疫苗及其制备方法和应用 | |
CN103301449B (zh) | 一种大规模培养树突状细胞疫苗的制备方法及其应用 | |
CN104789527B (zh) | 一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品 | |
CN107460167A (zh) | 一种无滋养细胞的nk细胞的扩增方法 | |
CN107541498A (zh) | 一种tcr基因修饰的cd8+t记忆性干细胞的制备方法及其用途 | |
CN105087488A (zh) | 一种肿瘤抗原诱导的dc-cik细胞的制备方法及应用 | |
CN101519646A (zh) | 一种cik细胞及其制备方法和细胞制剂 | |
CN105176927A (zh) | 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法 | |
CN104072599A (zh) | 一种多肽、采用其体外激活的树突状细胞及其用途 | |
EA030061B1 (ru) | Фармацевтические композиции и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток | |
CN103173411A (zh) | 一种制备树突状细胞的方法及其试剂盒 | |
CN103784950A (zh) | 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒 | |
CN104152411A (zh) | 一种自体树突状细胞激活肿瘤浸润性t淋巴细胞的制备方法及其应用 | |
CN103013914B (zh) | 体外培养杀伤性t细胞的方法 | |
CN105505871B (zh) | 一种有效扩增cik且提高其特异性杀瘤能力的方法 | |
CN102813916B (zh) | 一种快速获取树突状细胞疫苗的制备方法及其应用 | |
CN108642013A (zh) | 一种从脐带血中分离cd34造血干细胞扩大培养后大规模诱导制备树突状细胞方法 | |
CN101418283A (zh) | 一种简单高效地制备cik细胞的方法 | |
CN104906575A (zh) | LSECtin作为黑色素瘤免疫治疗的靶点 | |
CN106047809A (zh) | 一种联合tlr7配体同时扩增人cik/nk细胞的方法 | |
CN110205293A (zh) | 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用 | |
CN105238755A (zh) | 一种人参提取物fqr1及其在肿瘤免疫治疗中的应用 | |
CN104017770A (zh) | 一种利用糖脂制备cik细胞的方法 | |
CN101429495A (zh) | 一种人外周血来源造血干细胞的培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Xipusheng International Biotechnology Co., Ltd. Document name: Notification of Patent Invention Entering into Substantive Examination Stage |
|
DD01 | Delivery of document by public notice |
Addressee: Beijing Xipusheng International Biotechnology Co., Ltd. Document name: Notification of an Office Action |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Xipusheng International Biotechnology Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice |
Addressee: Beijing Xipusheng International Biotechnology Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Xipusheng International Biotechnology Co., Ltd. Document name: Notification of Termination of Patent Right |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150311 Termination date: 20180905 |